M. Fernández

机构：Universidad Autónoma de Madrid · ORCID：0000-0001-7468-2700

发表论文 52 篇 · 总被引 214 次 · h-index 7

代表论文

• Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial (2025 · Nature Medicine · 被引 125)
• Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study (2025 · Journal of Clinical Oncology · 被引 18)
• Abstract GS01-02: Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756 (2024 · Cancer Research · 被引 16)
• KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations. (2023 · Journal of Clinical Oncology · 被引 12)
• Pembrolizumab (pembro) + chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study. (2024 · Journal of Clinical Oncology · 被引 9)
• First-line pembrolizumab in patients with advanced non-small cell lung cancer and high PD-L1 expression: real-world data from a Spanish multicenter study (2024 · Frontiers in Oncology · 被引 7)